VIDEO: Can mantle cell lymphoma be cured? Expert explores next steps

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So I touched on that a minute ago when I was talking about p53 mutated, and should we say a highly aggressive, multiply relapsed, or all types of mantle cell lymphoma that can be a lot more challenging to treat. I think we're learning that if you relapse after CAR T, those are often very difficult to treat patients.

We've used bispecific antibodies in that space, and there have been some promising results, but certainly those remain challenging in poor prognosis patients. So that's a clear area where there's an unmet need. I do also think that the other major unmet need is, can we cure people? So again, if you think about how well we do with mantle cell lymphoma, compared to a few decades back when mantle cell lymphoma was really seen as a poor prognosis disease, we're seeing patients do a lot better. But obviously the next frontier, as it were, is to take these advances, and really step it up to the next level.

And we do see some promising additional agents being brought and added into the mix. And by that, I think of venetoclax, for example. There have been some studies, the ViPOR combination in relapsed patients appears promising. And so I think as we bring those additional agents into these combinations that include a BTK inhibitor, that include an anti-CD20 antibody, we may be able to get away from the old style chemotherapy into the new style targeted immunological, and shall we say, immune-modifying treatments that would allow us to have a better outcome, and obviously the final goal is potentially cure patients.